Association between BRAF<b><sup>V600E</sup></b> gene mutation and extrathyroidal extension in papillary thyroid carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHAN Ling ,  SUN Shengrong

Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, P. R. China;

Corresponding?author：

SUN Shengrong, Email: sun137@sina.com

Keywords：

BRAF^V600E gene mutation; papillary thyroid carcinoma; extrathyroidal extension

DOI：

10.7507/1007-9424.202012131

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate association between BRAF^V600E gene mutation and extrathyroidal extension (ETE) among patients with papillary thyroid carcinoma (PTC).Methods A retrospective study was conducted to collect all PTC surgical patients in the Renmin Hospital of Wuhan University from 2017 to 2019. The patients tested for BRAF^V600E gene mutation were selected, and the association between BRAF^V600E gene mutation and ETE were analyzed.Results The BRAF^V600E gene mutation test was performed only in 273 cases, 223 and 50 of whom were BRAF^V600E gene with and without mutation, respectively; 194 and 79 of whom had ETE and no ETE, respectively. Univariate analysis showed that the incidence rate with BRAF^V600E gene mutation was higher in the patients with ETE as compared with the patients without ETE (86.1% vs 70.9%, P=0.003) and the incidence rate of ETE was higher in the patients with BRAF^V600E gene mutaton than in the patients without BRAF^V600E gene mutaton (74.9% vs 54.0%, P=0.003). In addition, the incidence rates of ETE in the patients with tumor diameter >1 cm, bilaterality, and multifocality were higher than those in the patients with tumor diameter ≤1 cm (86.7% vs 61.3%, P<0.001), unilaterality (89.6% vs 63.8%, P<0.001), and single lesion (85.7% vs 60.9%, P<0.001), respectively. The incidence rate of ETE was increased with the increase of lymph node stage (P=0.003). Multivariate logistic regression analysis showed tumor size >1 cm [OR=3.606, 95%CI (1.758, 7.396), P<0.001], multifocality [OR=2.524, 95%CI (1.154, 5.519), P=0.020], with BRAF^V600E gene mutaton [OR=3.022, 95%CI (1.443, 6.326), P=0.003] were the risk factors for ETE.Conclusion The preliminary results of this study suggest that PTC patients with BRAF^V600E gene mutaton are more likely to gross ETE.

Citation： ZHAN Ling, SUN Shengrong. Association between BRAF^V600E gene mutation and extrathyroidal extension in papillary thyroid carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(9): 1159-1164. doi: 10.7507/1007-9424.202012131 Copy

1.	Zhao L, Pang P, Zang L, et al. Features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China between 1994 and 2015: a retrospective study. BMJ Open, 2019, 9(1): e023334.
2.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021 Feb 4. doi: 10.3322/caac.21660. Online ahead of print.
3.	Zhang J, Cheng X, Shen L, et al. The association between lymph node stage and clinical prognosis in thyroid cancer. Front Endocrinol (Lausanne), 2020, 11: 90.
4.	黃璐, 李超, 王薇, 等. 甲狀腺癌腺外侵犯的意義及最新研究進展. 中華耳鼻咽喉頭頸外科雜志, 2019, 54(9): 717-720.
5.	中華人民共和國國家衛生健康委員會. 甲狀腺癌診療規范(2018年版). 中華普通外科學文獻(電子版), 2019, 13(1): 1-15.
6.	Kim KJ, Kim SG, Tan J, et al. BRAF^V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. Eur J Cancer, 2020, 124: 161-169.
7.	Huang Y, Qu S, Zhu G, et al. BRAF^V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment. J Natl Cancer Inst, 2018, 110(4): 362-370.
8.	Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev, 2019, 40(6): 1573-1604.
9.	McLeod DSA, Zhang L, Durante C, et al. Contemporary debates in adult papillary thyroid cancer management. Endocr Rev, 2019, 40(6): 1481-1499.
10.	宋創業, 嚴麗, 孟艷林, 等. BRAF^V600E突變在cN0期PTMC頸中央區淋巴結轉移中的預測價值. 中華普外科手術學雜志(電子版), 2020, 14(6): 631-634.
11.	Gouveia C, Can NT, Bostrom A, et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg, 2013, 139(11): 1164-1170.
12.	Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1): 1-133.
13.	Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th edn. New York, NY: Springer International Publishing, 2017.
14.	Sugino K, Nagahama M, Kitagawa W, et al. Risk stratification of pediatric patients with differentiated thyroid cancer: is total thyroidectomy necessary for patients at any risk? Thyroid, 2020, 30(4): 548-556.
15.	宋韞韜, 于文斌, 魏煒, 等. 甲狀腺乳頭狀癌腺外侵犯相關因素分析. 中國實用外科雜志, 2017, 37(11): 1272-1275.
16.	Li G, Li R, Song L, et al. Implications of extrathyroidal extension invading only the strap muscles in papillary thyroid carcinomas. Thyroid, 2020, 30(1): 57-64.
17.	崔文霞, 朱有志, 鄭珂, 等. 甲狀腺乳頭狀癌BRAF^V600E基因突變與蛋白表達的臨床研究. 中華實驗外科雜志, 2018, 35(3): 522-524.
18.	Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF^V600E mutation in papillary thyroid cancer: a subgroup analysis of 3 130 cases in a single center. Thyroid, 2013, 23(11): 1423-1430.
19.	Yan C, Huang M, Li X, et al. Relationship between BRAF^V600E and clinical features in papillary thyroid carcinoma. Endocr Connect, 2019, 8(7): 988-996.
20.	王越, 趙文娟. 橋本氏甲狀腺炎合并PTC臨床病理特征與BRAF^V600E基因突變的相關性研究, 青島大學, 2019.
21.	Kim WW, Ha TK, Bae SK. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol Head Neck Surg, 2018, 47(1): 4.
22.	Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAF^V600E in papillary thyroid carcinoma. Endocr Relat Cancer, 2016, 23(1): 27-34.
23.	Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res, 2019, 25(3): 1191-1197.
24.	Pess?a-Pereira D, Medeiros MFDS, Lima VMS, et al. Association between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metab, 2019, 63(2): 97-106.
25.	Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: A review. JAMA, 2019, 322(2): 153-160.
26.	Vita R, Ieni A, Tuccari G, et al. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord, 2018, 19(4): 301-309.
27.	Marotta V, Sciammarella C, Chiofalo MG, et al. Hashimoto’s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer, 2017, 24(9): 485-493.
28.	張艷, 王文棟, 蘭霞斌, 等. 甲狀腺乳頭狀癌伴發橋本甲狀腺炎的臨床研究. 中國癌癥雜志, 2019, 29(12): 948-954.
29.	稅春燕, 李超, 覃綱, 等. 甲狀腺乳頭狀癌臨床病理特征對頸部淋巴結轉移風險預測. 中華腫瘤防治雜志, 2019, 26(13): 952-958.
30.	Jain NK, Mostoufi-Moab S, Hawkes CP, et al. Extrathyroidal extension is an important predictor of regional lymph node metastasis in pediatric differentiated thyroid cancer. Thyroid, 2020, 30(7): 1037-1043.
31.	Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 2001, 86(4): 1447-1463.
32.	Sulaieva O, Chernenko O, Chereshneva Y, et al. Thyroid stimulating hormone levels and BRAF^V600E mutation contribute to pathophysiology of papillary thyroid carcinoma: Relation to outcomes? Pathophysiology, 2019, 26(2): 129-135.

1. Zhao L, Pang P, Zang L, et al. Features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China between 1994 and 2015: a retrospective study. BMJ Open, 2019, 9(1): e023334.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021 Feb 4. doi: 10.3322/caac.21660. Online ahead of print.
3. Zhang J, Cheng X, Shen L, et al. The association between lymph node stage and clinical prognosis in thyroid cancer. Front Endocrinol (Lausanne), 2020, 11: 90.
4. 黃璐, 李超, 王薇, 等. 甲狀腺癌腺外侵犯的意義及最新研究進展. 中華耳鼻咽喉頭頸外科雜志, 2019, 54(9): 717-720.
5. 中華人民共和國國家衛生健康委員會. 甲狀腺癌診療規范(2018年版). 中華普通外科學文獻(電子版), 2019, 13(1): 1-15.
6. Kim KJ, Kim SG, Tan J, et al. BRAF^V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. Eur J Cancer, 2020, 124: 161-169.
7. Huang Y, Qu S, Zhu G, et al. BRAF^V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment. J Natl Cancer Inst, 2018, 110(4): 362-370.
8. Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev, 2019, 40(6): 1573-1604.
9. McLeod DSA, Zhang L, Durante C, et al. Contemporary debates in adult papillary thyroid cancer management. Endocr Rev, 2019, 40(6): 1481-1499.
10. 宋創業, 嚴麗, 孟艷林, 等. BRAF^V600E突變在cN0期PTMC頸中央區淋巴結轉移中的預測價值. 中華普外科手術學雜志(電子版), 2020, 14(6): 631-634.
11. Gouveia C, Can NT, Bostrom A, et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg, 2013, 139(11): 1164-1170.
12. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1): 1-133.
13. Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th edn. New York, NY: Springer International Publishing, 2017.
14. Sugino K, Nagahama M, Kitagawa W, et al. Risk stratification of pediatric patients with differentiated thyroid cancer: is total thyroidectomy necessary for patients at any risk? Thyroid, 2020, 30(4): 548-556.
15. 宋韞韜, 于文斌, 魏煒, 等. 甲狀腺乳頭狀癌腺外侵犯相關因素分析. 中國實用外科雜志, 2017, 37(11): 1272-1275.
16. Li G, Li R, Song L, et al. Implications of extrathyroidal extension invading only the strap muscles in papillary thyroid carcinomas. Thyroid, 2020, 30(1): 57-64.
17. 崔文霞, 朱有志, 鄭珂, 等. 甲狀腺乳頭狀癌BRAF^V600E基因突變與蛋白表達的臨床研究. 中華實驗外科雜志, 2018, 35(3): 522-524.
18. Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF^V600E mutation in papillary thyroid cancer: a subgroup analysis of 3 130 cases in a single center. Thyroid, 2013, 23(11): 1423-1430.
19. Yan C, Huang M, Li X, et al. Relationship between BRAF^V600E and clinical features in papillary thyroid carcinoma. Endocr Connect, 2019, 8(7): 988-996.
20. 王越, 趙文娟. 橋本氏甲狀腺炎合并PTC臨床病理特征與BRAF^V600E基因突變的相關性研究, 青島大學, 2019.
21. Kim WW, Ha TK, Bae SK. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol Head Neck Surg, 2018, 47(1): 4.
22. Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAF^V600E in papillary thyroid carcinoma. Endocr Relat Cancer, 2016, 23(1): 27-34.
23. Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res, 2019, 25(3): 1191-1197.
24. Pess?a-Pereira D, Medeiros MFDS, Lima VMS, et al. Association between BRAF^V600E mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metab, 2019, 63(2): 97-106.
25. Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: A review. JAMA, 2019, 322(2): 153-160.
26. Vita R, Ieni A, Tuccari G, et al. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord, 2018, 19(4): 301-309.
27. Marotta V, Sciammarella C, Chiofalo MG, et al. Hashimoto’s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer, 2017, 24(9): 485-493.
28. 張艷, 王文棟, 蘭霞斌, 等. 甲狀腺乳頭狀癌伴發橋本甲狀腺炎的臨床研究. 中國癌癥雜志, 2019, 29(12): 948-954.
29. 稅春燕, 李超, 覃綱, 等. 甲狀腺乳頭狀癌臨床病理特征對頸部淋巴結轉移風險預測. 中華腫瘤防治雜志, 2019, 26(13): 952-958.
30. Jain NK, Mostoufi-Moab S, Hawkes CP, et al. Extrathyroidal extension is an important predictor of regional lymph node metastasis in pediatric differentiated thyroid cancer. Thyroid, 2020, 30(7): 1037-1043.
31. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 2001, 86(4): 1447-1463.
32. Sulaieva O, Chernenko O, Chereshneva Y, et al. Thyroid stimulating hormone levels and BRAF^V600E mutation contribute to pathophysiology of papillary thyroid carcinoma: Relation to outcomes? Pathophysiology, 2019, 26(2): 129-135.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Association between BRAF^V600E gene mutation and extrathyroidal extension in papillary thyroid carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Association between BRAFV600E gene mutation and extrathyroidal extension in papillary thyroid carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Association between BRAF^V600E gene mutation and extrathyroidal extension in papillary thyroid carcinoma